AngioDynamics, Inc. (ANGO) Shares Bought by American Century Companies Inc.
American Century Companies Inc. increased its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 9.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 334,002 shares of the medical instruments supplier’s stock after buying an additional 28,067 shares during the period. American Century Companies Inc. owned 0.91% of AngioDynamics worth $5,708,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of ANGO. UBS Asset Management Americas Inc. purchased a new stake in shares of AngioDynamics in the first quarter worth about $191,000. Legal & General Group Plc lifted its position in shares of AngioDynamics by 2.2% in the first quarter. Legal & General Group Plc now owns 52,401 shares of the medical instruments supplier’s stock worth $910,000 after buying an additional 1,117 shares in the last quarter. Vanguard Group Inc. increased its stake in AngioDynamics by 7.4% during the first quarter. Vanguard Group Inc. now owns 1,694,290 shares of the medical instruments supplier’s stock worth $29,396,000 after acquiring an additional 116,814 shares during the last quarter. Geode Capital Management LLC increased its stake in AngioDynamics by 21.5% during the first quarter. Geode Capital Management LLC now owns 366,148 shares of the medical instruments supplier’s stock worth $6,352,000 after acquiring an additional 64,707 shares during the last quarter. Finally, Morgan Stanley increased its stake in AngioDynamics by 2.0% during the first quarter. Morgan Stanley now owns 240,773 shares of the medical instruments supplier’s stock worth $4,176,000 after acquiring an additional 4,669 shares during the last quarter. Institutional investors own 96.21% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “AngioDynamics, Inc. (ANGO) Shares Bought by American Century Companies Inc.” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/angiodynamics-inc-ango-shares-bought-by-american-century-companies-inc/1721367.html.
Shares of AngioDynamics, Inc. (NASDAQ ANGO) opened at $17.34 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.48 and a current ratio of 2.34. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.85. The firm has a market capitalization of $639.59, a P/E ratio of 25.25, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The company had revenue of $85.40 million for the quarter, compared to the consensus estimate of $86.12 million. AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The company’s revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 earnings per share. equities analysts predict that AngioDynamics, Inc. will post 0.65 EPS for the current fiscal year.
Several brokerages have weighed in on ANGO. Canaccord Genuity reissued a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a research note on Sunday, October 8th. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Tuesday, October 3rd. KeyCorp reissued a “hold” rating on shares of AngioDynamics in a research note on Friday, September 29th. Finally, BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $18.60.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.